Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs LTC Properties Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.43 (market cap $29.60B), while LTC Properties Inc trades at $38.73 (market cap $2.05B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 14.4× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.98% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LTC | |
|---|---|---|
Market Cap | $29.60B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $42.81 |
52-Week Low | $205.48 | $33.98 |
Enterprise Value | $27.56B | $2.79B |
Dividend Yield | — | 5.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
LTC Properties trades at $38.77, down 1.65% on the day, with a bearish technical signal and mixed earnings history. The company reported revenue of $262.85 million in 2025, with a net income margin of 38.93%, and maintains a P/E ratio of 13.61. Recent news highlights active SHOP portfolio expansion, including a $95 million acquisition, and consistent monthly dividends of $0.19 per share.
Outlook remains cautious due to bearish technicals and mixed analyst sentiment, though strong profitability and dividend yield offer support. Key risks include execution of aggressive acquisition strategy and debt levels. Upside depends on sustained revenue growth and successful integration of new properties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
